<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01420627</url>
  </required_header>
  <id_info>
    <org_study_id>STP-2279-002</org_study_id>
    <nct_id>NCT01420627</nct_id>
  </id_info>
  <brief_title>EZN-2279 in Patients With ADA-SCID</brief_title>
  <official_title>A Study of EZN-2279 (Polyethylene Glycol Recombinant Adenosine Deaminase [PEG-rADA]) Administered as a Weekly Intramuscular Injection in Patients With Adenosine Deaminase (ADA)-Deficient Combined Immunodeficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leadiant Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leadiant Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of
      EZN-2279 in patients with ADA-deficient combined immunodeficiency currently being treated
      with Adagen.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>total erythrocyte dAXP concentration from a trough blood sample</measure>
    <time_frame>through 21 weeks of EZN-2279 treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma ADA activity</measure>
    <time_frame>through 21 weeks of EZN-2279 treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune status</measure>
    <time_frame>through end of EZN-2279 treatment</time_frame>
    <description>includes absolute lymphocyte counts, lymphocyte subset analysis, quantitative immunoglobulin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>through end of EZN-2279 study treatment</time_frame>
    <description>adverse events, serious adverse events, physical examinations, laboratory evaluations and immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Status</measure>
    <time_frame>through end of EZN-2279 treatment</time_frame>
    <description>infection rate, incidence and duration of hospitalizations, overall survival, performance status</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>ADA-SCID</condition>
  <condition>Adenosine Deaminase Deficiency</condition>
  <condition>Severe Combined Immunodeficiency</condition>
  <arm_group>
    <arm_group_label>EZN-2279</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients crossed over to receive EZN-2279 following an Adagen lead-in period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adagen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients start on Adagen and cross over to experimental EZN-2279 treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EZN-2279</intervention_name>
    <description>weekly administration of EZN-2279 via IM injection</description>
    <arm_group_label>EZN-2279</arm_group_label>
    <other_name>rADA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adagen</intervention_name>
    <arm_group_label>Adagen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of ADA-deficient combined immunodeficiency

          2. Stable clinical status while receiving therapy with Adagen®. Patients previously
             receiving gene therapy or undergoing hematopoietic stem cell transplantation who still
             require Adagen® treatment are eligible. The dose of Adagen® must be stable for at
             least 3 months prior to study entry.

          3. Have both during the Adagen® Lead-in phase of the study:

               1. Trough plasma ADA activity &gt;15 μmol/h/mL while receiving Adagen®

               2. Total erythrocyte dAXP ≤0.02 μmol/mL from a trough blood sample

          4. Patients or parent/guardian must be capable of understanding the protocol requirements
             and risks and providing written informed assent/consent

        Exclusion Criteria:

          1. Autoimmunity requiring immunosuppressive treatment

          2. Patients with neutralizing anti-Adagen® antibodies at screening evaluation.

          3. Severe thrombocytopenia (platelet count &lt;50 x 109/L)

          4. Current participation in other therapeutic protocols for ADA-deficient combined
             immunodeficiency

          5. Current or prior participation in another clinical study with an investigational agent
             and/or use of an investigational drug in the 30 days before study entry.

          6. Known planned participation in a gene-therapy study for the planned duration of this
             study

          7. Any condition that, in the opinion of the PI or Sigma-Tau, makes the patient
             unsuitable for the study

          8. Inability or unwillingness to administer Adagen® or EZN-2279 on a one time per week
             regimen

          9. Inability to comply with the study protocol

         10. Female patients who are pregnant or lactating

         11. Female patients who are breast-feeding

         12. Female subjects of childbearing potential who are not using an FDA approved birth
             control method
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daniel Falleroni</last_name>
    <phone>301-948-1041</phone>
    <phone_ext>5447</phone_ext>
    <email>Daniel.Falleroni@Leadiant.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Scott Rodgers</last_name>
    <phone>301-670-1565</phone>
    <email>Scott.Rodgers@Leadiant.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greg Balagot</last_name>
      <phone>323-361-8569</phone>
      <email>gbalagot@chla.edu</email>
    </contact>
    <investigator>
      <last_name>Neena Kapoor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Shannon</last_name>
      <phone>415-502-6057</phone>
      <email>heidi.shannon@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Morna Dorsey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Women and Children's Hospital of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14222</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena McClenahan</last_name>
      <email>hmcclenahan@upa.chob.edu</email>
    </contact>
    <investigator>
      <last_name>Heather Lehman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gayle Krenik</last_name>
      <phone>718-405-8830</phone>
      <email>gkreinik@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Arye Rubinstein, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State College of Medicine The Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Stokes</last_name>
      <phone>717-531-7765</phone>
      <email>jstokes1@hmc.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Tracy Fausnight, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2011</study_first_submitted>
  <study_first_submitted_qc>August 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2011</study_first_posted>
  <last_update_submitted>October 27, 2017</last_update_submitted>
  <last_update_submitted_qc>October 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
    <mesh_term>Agammaglobulinemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

